May. 29, 2019—P-glycoprotein distinguishes between chemicals that it will expel from a cell and inhibitors that block its action.
May. 3, 2019—Malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers. Although rare — about 20 to 25 new cases are diagnosed annually in the United States — there is no standard effective treatment for the disease, which is driven by loss of an anti-cancer protein called SNF5. The chances are very small that a child will survive a year after MRT diagnosis.
Jan. 31, 2019—A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.
Jan. 23, 2019—Cancer Research UK has awarded a 20-million-pound grant (about $25 million U.S.) to a team of international investigators, including Vanderbilt’s James Goldenring, MD, PhD, to study inflammation-related cancers.
GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment
Jan. 7, 2019—GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies.
Nov. 15, 2018—In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have shown that heart and vessel complications include myocarditis, pericarditis, vasculitis and arrhythmias, and that they occur early in the course of treatment.